EW's Q4 Earnings Miss Estimates, Revenues Up Y/Y, Stock Climbs

Key Takeaways EW reports Q4 adjusted EPS of 58 cents, missing estimates, while revenues rose 13.3% to $1.57B.EW's TAVR sales rose 12% to $1.16B, and TMTT jumped 48.3% on strong SAPIEN, PASCAL and EVOQUE adoption.EW guides 2026 sales growth of 8%-10% and EPS of $2.90-$3.05, expressing confidence despite margin pressure.Edwards Lifesciences Corporation (EW) reported fourth-quarter 2025 adjusted earnings per share (EPS) of 58 cents, which fell short of the Zacks Consensus Estimate by 5.89%. The figure decrease ...